<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1126">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146492</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02590-57</org_study_id>
    <nct_id>NCT05146492</nct_id>
  </id_info>
  <brief_title>Pericardial Effusion From Acute Myocardial Infarction: Contributing Factors and Prognosis at One Year (EPERICARDIM)</brief_title>
  <acronym>EPERICARDIM</acronym>
  <official_title>Pericardial Effusion From Acute Myocardial Infarction: Contributing Factors and Prognosis at One Year (EPERICARDIM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramsay Générale de Santé</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Clinical Trial Experts Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramsay Générale de Santé</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to clarify, in patients with more or less abundant pericardial effusion in&#xD;
      the acute phase of a myocardial infarction, the correlation between the existence of this&#xD;
      effusion during the acute phase with clinical parameters, biological, angiographic,&#xD;
      therapeutic and with transmurality, extent, microvascular obstruction and intra myocardial&#xD;
      hemorrhage found on MRI made beyond one week and before the 3rd month of the constitution of&#xD;
      the necrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">July 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One-year mortality rate of patients with pericardial effusion</measure>
    <time_frame>1 year</time_frame>
    <description>One-year mortality rate of patients with pericardial effusion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Pericardial Effusion</condition>
  <arm_group>
    <arm_group_label>Patient with acute myocardial infarction without pericardial effusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with acute myocardial infarction and pericardial effusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI with gadolinium contrast media injection</description>
    <arm_group_label>Patient with acute myocardial infarction and pericardial effusion</arm_group_label>
    <arm_group_label>Patient with acute myocardial infarction without pericardial effusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient between 18 and 90 years old&#xD;
&#xD;
          -  Patient admitted to the acute or semi-recent phase (within the next fifteen days) of a&#xD;
             myocardial infarction (primary or recurrent myocardial infarction) documented by a&#xD;
             significant enzymatic release of troponin (threshold value at 100) in the course of:&#xD;
             chest pain or shock, or flare-up of heart failure (left or global) or successfully&#xD;
             resuscitated cardiac arrest, or paroxysmal ventricular arrhythmia with or without sus&#xD;
             shift of the ST segment on the input trace, with or without Q wave of necrosis formed.&#xD;
             This IDM may or may not be complicated by a more or less abundant pericardial effusion&#xD;
             of more than 10 mm in the left parasternal, which may in the extreme be the cause of&#xD;
             tamponade;&#xD;
&#xD;
          -  Subject affiliated or beneficiary of a social security scheme;&#xD;
&#xD;
          -  Patient having signed the free and informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a pericardial detachment of less than 10 mm, or only systolic;&#xD;
&#xD;
          -  Patient who had a break-in during the primary angioplasty guide or complicated&#xD;
             coronary dissection extravasation with secondary pericardial effusion;&#xD;
&#xD;
          -  Patient with advanced chronic renal failure&#xD;
&#xD;
          -  Patient unable to perform an MRI (with a defibrillator or pacemaker).&#xD;
&#xD;
          -  Known allergy to contrast agents, in particular gadolinium&#xD;
&#xD;
          -  claustrophobic patient;&#xD;
&#xD;
          -  Protected patient: adult under guardianship or other legal protection, deprived of&#xD;
             liberty by judicial or administrative decision;&#xD;
&#xD;
          -  Pregnant or breastfeeding woman;&#xD;
&#xD;
          -  Patient hospitalized without consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-François Oudet</last_name>
    <phone>0683346567</phone>
    <email>jf.oudet@ecten.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Hélène Barba</last_name>
    <email>mh.barba@ecten.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Private Hospital of Parly II-Le Chesnay</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Oudet</last_name>
      <phone>0683346567</phone>
      <email>jf.oudet@ecten.eu</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Hélène Barba</last_name>
      <email>mh.barba@ecten.eu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Pericardial Effusion</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

